Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Among authors: berenguer j. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.
Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
Berenguer J, González J, Pulido F, Padilla B, Casado JL, Rubio R, Arribas JR; Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis. Berenguer J, et al. Clin Infect Dis. 2002 Feb 1;34(3):394-7. doi: 10.1086/338401. Epub 2001 Dec 19. Clin Infect Dis. 2002. PMID: 11753827 Clinical Trial.
Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.
Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lacruz Rodrigo J, Mallolas J, de Miguel V; GESIDA 11/99 Study Group. Berenguer J, et al. Clin Infect Dis. 2003 Apr 15;36(8):1047-52. doi: 10.1086/374048. Epub 2003 Apr 2. Clin Infect Dis. 2003. PMID: 12684918
Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].
Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Berenguer J, et al. Enferm Infecc Microbiol Clin. 2004 Mar;22(3):160-76. doi: 10.1016/s0213-005x(04)73057-8. Enferm Infecc Microbiol Clin. 2004. PMID: 14987537 Review. English, Spanish.
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-Aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Santamaría JM, Kindelán JM, Ribera E, Segura F; Grupo de Estudio de Sida; Consejo Asesor Clínico del Plan Nacional sobre el Sida del Ministerio de Sanidad y Consumo. Iribarren JA, et al. Among authors: berenguer j. Enferm Infecc Microbiol Clin. 2004 Dec;22(10):564-642. doi: 10.1157/13069520. Enferm Infecc Microbiol Clin. 2004. PMID: 15596051 Spanish.
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR. Montes ML, et al. Among authors: berenguer j. J Antimicrob Chemother. 2005 May;55(5):800-4. doi: 10.1093/jac/dki063. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761071 Clinical Trial.
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM, Miguélez M, Hernández-Quero J, Flores J, Soriano V, Santos I, Podzamczer D, Sala M, Camba M, Resino S; Spanish Abacavir, Lamivudine, and Zidovudine Cohort Study Group. Berenguer J, et al. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154-9. doi: 10.1097/01.qai.0000194231.08207.8a. J Acquir Immune Defic Syndr. 2006. PMID: 16394846
880 results